Reuters logo
BRIEF-Novartis confirms 5 year data for first, only fully-human IL-17A inhibitor Cosentyx reinforcing sustained efficacy, safety profile in psoriasis
July 14, 2017 / 8:06 PM / in 4 months

BRIEF-Novartis confirms 5 year data for first, only fully-human IL-17A inhibitor Cosentyx reinforcing sustained efficacy, safety profile in psoriasis

July 14 (Reuters) - Novartis AG:

* Novartis confirms 5 year data for first and only fully-human il-17a inhibitor cosentyx® reinforcing sustained efficacy and safety profile in psoriasis Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below